Antitumor potential of SLPI promoter controlled recombinant caspase-3 expression in laryngeal carcinoma

Cancer Gene Therapy

Volumn 19, Issue 5, 2012, Pages 328-335

  Chen, J ^a,b   Yang, B ^a,b   Zhang, S ^a   Ling, Y ^a   Ye, J ^a   Jia, Z ^b   Cao, J ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

apoptosis; caspase 3; gene therapy; larynx; squamous cell carcinoma; tissue specific promoter

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CASPASE 3; GENOMIC DNA; LUCIFERASE; RECOMBINANT CASPASE 3; RECOMBINANT PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA ANTIGEN; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; GENE EXPRESSION; HEP 2 CELL; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; LARYNX CARCINOMA; LIVER TOXICITY; MOLECULAR CLONING; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; PROMOTER REGION; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; UMBILICAL VEIN ENDOTHELIAL CELL; WEIGHT REDUCTION;

ANIMALS; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENE THERAPY; HUMANS; LARYNGEAL NEOPLASMS; MICE; MICE, NUDE; PROMOTER REGIONS, GENETIC; SECRETORY LEUKOCYTE PEPTIDASE INHIBITOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84862803111     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2012.5     Document Type: Article

References (31)

1. Surveillance, epidemiology and end results program web site. Available at URL: http://seer.cancer.gov/statfacts/html/laryn.html; accessed May 1st, 2011.
2. Nakano H, Kishida T, Asada H, Shin-Ya M, Shinomiya T, Imanishi J et al. Interleukin-triggers both cellular and humoral immune responses leading to therapeutic antitumor effects against head and neck squamous cell carcinoma. J Gene Med 2006; 8: 90-99. (Pubitemid 43169385)
3. Saukkonen K, Hemminki A. Tissue-specific promoters for cancer gene therapy. Expert Opin Biol Ther 2004; 4: 683-696. (Pubitemid 38667814)
4. Barker SD, Coolidge CJ, Kanerva A, Hakkarainen T, Yamamoto M, Liu B et al. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med 2003; 5: 300-310. (Pubitemid 40310382)
5. Oshikiri T, Miyamoto M, Hiraoka K, Shichinohe T, Kawarada Y, Kato K et al. Transcriptional targeting of adenovirus vectors with the squamous cell carcinoma-specific antigen-2 promoter for selective apoptosis induction in lung cancer. Cancer Gene Ther 2006; 13: 856-886.
6. Murakami A, Suminami Y, Sakaguchi Y, Nawata S, Numa F, Kishi F et al. Specific detection and quantitation of SCC antigen 1 and SCC antigen 2 mRNAs by fluorescence-based asymmetric semi-nested reverse transcription PCR. Tumour Biol 2000; 21: 224-234. (Pubitemid 30435488)
7. Abe T, Tominaga Y, Kikuchi T, Watanabe A, Satoh K, Watanabe Y et al. Bacterial pneumonia causes augmented expression of the secretory leukoprotease inhibitor gene in the murine lung. Am J Respir Crit Care Med 1997; 156:1235-1240.
8. Dasgupta S, Tripathi PK, Qin H, Bhattacharya-Chatterjee M, Valentino J, Chatterjee SK. Identification of molecular targets for immunotherapy of patients with head and neck squamous cell carcinoma. Oral Oncol 2006; 42: 306-316. (Pubitemid 43246763)
9. Srinivasula SM, Ahmad M, MacFarlane M, Luo Z, Huang Z, Fernandes-Alnemri T. Generation of constitutively active recombinant caspases-3 and-6 by rearrangement of their subunits. J Biol Chem 1998; 273: 10107-10111. (Pubitemid 28227608)
10. Cam L, Boucquey A, Coulomb-L'hermine A, Weber A, Horellou P. Gene transfer of constitutively active caspase-3 induces apoptosis in a human hepatoma cell line. J Gene Med 2005; 7: 30-38.
11. Kikuchi T, Abe T, Satoh K, Narumi K, Sakai T, Abe S et al. Cis-acting region associated with lung cell-specific expression of the secretory leukoprotease inhibitor gene. Am J Respir Cell Mol Biol 1997; 17: 361-367. (Pubitemid 127500841)
12. Li F, Altieri DC. Transcriptional analysis of human survivin gene expression. Biochem J 1999; 2: 305-311. (Pubitemid 30011584)
13. Jonsson N, Gullberg M, Israelsson S, Lindberg AM. A rapid and efficient method for studies of virus interaction at the host cell surface using enteroviruses and real-time PCR. Virol J 2009; 6: 217.
14. Glasgow JN, Everts M, Curiel DT. Transductional targeting of adenovirus vectors for gene therapy. Cancer Gene Ther 2006; 13: 830-844.
15. Willhauck MJ, Sharif Samani BR, Klutz K, Cengic N, Wolf I, Mohr L et al. Alphafetoprotein promoter-targeted sodium iodide symporter gene therapy of hepatocellular carcinoma. Gene Ther 2007; 15: 214-223.
16. Rein DT, Breidenbach M, Curiel DT. Current developments in adenovirus-based cancer gene therapy. Future Oncol 2006; 2: 137-143.
17. Wang Z, Sun Y. Targeting p53 for novel anticancer therapy. Transl Oncol 2010; 3:1-12.
18. Oh YK, Park TG. siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 2009; 61: 850-862.
19. Mossoba ME, Medin JA. Cancer immunotherapy using virally transduced dendritic cells: animal studies and human clinical trials. Expert Rev Vaccines 2006; 5:717-732. (Pubitemid 46021052)
20. Portsmouth D, Hlavaty J, Renner M. Suicide genes for cancer therapy. Mol Aspects Med 2007; 28: 4-41.
21. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther 2005; 16: 1016-1027. (Pubitemid 41324561)
22. Xian J, Lin Y, Liu Y, Gong P, Liu S. Combined p14ARF and antisense EGFR potentiate the efficacy of adenovirus-mediated gene therapy in laryngeal squamous cell carcinoma (LSCC). DNA Cell Biol 2007; 26: 71-79. (Pubitemid 46363872)
23. Hamstra DA, Rice DJ, Fahmy S, Ross BD, Rehemtulla A. Enzyme/prodrug therapy for head and neck cancer using a catalytically superior cytosine deaminase. Hum Gene Ther 1999; 10: 1993-2003. (Pubitemid 29387913)
24. Heilbronn R, Weger S. Viral vectors for gene transfer: current status of gene therapeutics. Handb Exp Pharmacol 2010; 197: 143-170.
25. Caldas H, Jaynes FO, Boyer MW, Hammond S, Altura RA. Survivin and Granzyme Binduced apoptosis, a novel anticancer therapy. Mol Cancer Ther 2006; 5: 693-703.
26. Lorenzo HK, Susin SA. Therapeutic potential of AIF-mediated caspase-independent programmed cell death. Drug Resist Updat 2007; 10: 235-255.
27. Gross A. BID as a double agent in cell life and death. Cell Cycle 2006; 5: 582-584.
28. Weiwei M, Zhenhua X, Feng L, Hang N, Yuyang J. A significant increase of RNAi efficiency in human cells by the CMV enhancer with a tRNAlys promoter. J Biomed Biotechnol 2009; 2009: 514287.
29. Curiel DT. The development of conditionally replicative adenoviruses for cancer therapy. Clin Cancer Res 2000; 6: 3395-3399.
30. Jiang H, Gomez-Manzano C, Lang FF, Alemany R, Fueyo J. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. Curr Gene Ther 2009; 9: 422-427.
31. Yang ZR, Wang HF, Zhao J, Peng YY, Wang J, Guinn BA. Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy. Cancer Gene Ther 2007; 14: 599-615. (Pubitemid 46912038)